Rapamycin (Sirolimus)
mTORC1 inhibitor. Suppresses autophagy signaling enough to extend lifespan in multiple animal models. Used off-label for longevity at low intermittent doses (Kaeberlein protocol).
Evidence is experimental. Most claims trace to limited human studies or animal models. Treat as a research direction, not a protocol.
mTOR inhibition extends lifespan in yeast, worms, flies, and mice — even when started in late life. The Kaeberlein protocol (1–6 mg/week intermittently) aims to get autophagy benefits without continuous immunosuppression. No longevity RCTs in humans exist. FDA-approved for transplant rejection (not longevity). Significant side-effect profile at therapeutic doses; low-dose intermittent may be safer but is unstudied.
Immunosuppressive at therapeutic doses — increased infection risk. Mouth sores (aphthous ulcers), hyperlipidemia, hyperglycemia. Off-label use is unmonitored. Requires a prescribing provider willing to prescribe off-label. Interactions with CYP3A4 inhibitors (grapefruit, ketoconazole) can cause dose stacking.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- DMechanistic / anecdotal
Rapamycin (Sirolimus) — primary mechanism: mtorc1 inhibitor. suppresses autophagy signaling enough to extend lifespan in multiple animal models. used off-label for longevity at low intermittent doses (kaeberlein protocol).
3 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
FDA-approved (transplant rejection). Off-label for longevity.